Visit the other websites


Our mission

At IBA we dare to develop innovative solutions pushing back the limits of science. We share ideas and know-how with our customers, our partners and leading experts to bring new solutions for the diagnosis and treatment of cancer and for the benefits of patients. We care of the well-being of patients and stakeholders as it is together that we complete our mission to Protect Enhance and Save lives.



Proton therapy is a form of radiotherapy considered by many specialists to be the most advanced and targeted cancer treatment. Because of its precision to target the tumor and its property to spare healthy tissues, proton therapy results in fewer side effects for the benefit of patients.

More than half of proton therapy facilities worldwide are IBA systems.

  • years of
  • reference
  • patients
Proton therapy website


For both diagnosis and therapy, delivering exactly the prescribed dose to a precisely defined area in the patient’s body is crucial.

IBA offers a full range of monitoring equipment and software enabling radiologists to perform the necessary checks and calibration procedures.

  • supplier
    of Innovative
  • +3500 hospitals
    trust IBA
  • supplier
    of Innovative
Dosimetry website


IBA RadioPharma Solutions offers solutions that combines equipment (cyclotron, synthesizer,...) and services for the establishment of radiopharmaceutical production centres in total compliance with current norms.

  • Synthera :
    The most
  • + 230
  • + 250
  • Up to 21 Ci
Radiopharma website

Industrial and
Sterilization Solutions

IBA Industrial focuses on two markets: the sterilization of single-use medical products and the improvement of the physical properties of polymers (crosslinking). IBA technology is faster and avoids all contamination by chemical products or radioactive.

  • e-beam
    installed for
  • of installed
    power in e-beam
Industrial and Sterilization solutions website

Management team

Download the Code of Business Conduct

  • Jean-Marc Bothy

    Chief Strategy Officer, based in Louvain-la-Neuve, Belgium

  • Yves Jongen

    Founder and Chief Research Officer, based in Louvain-la-Neuve, Belgium

    About Yves
  • Olivier Legrain

    Chief Executive Officer, based in Louvain-la-Neuve, Belgium

    About Olivier
  • Rob Plompen

    President IBA Dosimetry, based in Schwarzenbruck, Germany

  • Soumya Chandramouli

    Chief Financial Officer, Based in Louvain-la-Neuve

  • Frédéric Nolf

    Chief Human Resources Officer, based in Louvain-la-Neuve Belgium


Olivier Legrain

Chief Executive Officer
based in Louvain­-la-­Neuve, Belgium

Olivier Legrain, married and father of two children, graduated in economics from the Free University of Brussels (ULB) in 1992.

After four years as auditor with Didier Claes and Associates, he joined IBA SA in 1996 as Controller and was particularly involved in the IPO of the company. In 1998 he was appointed Chief Financial Officer (CFO) of Scanditronix Medical AB Sweden, the new subsidiary of IBA’s dosimetry activities.

He returned to the Belgian headquarters for a period of two years before taking the roles of Chairman and Chief Executive Officer (CEO) of Wellhöfer Scanditronix AB from 2001 to 2003. After having successfully lead the dosimetry branch of operations, Olivier Legrain took control of IBA Molecular in 2003 as President.

In 2011, he became responsible for establishing the future strategy of the IBA Group with his new role as Chief Strategy Officer (CSO), a strategy that he will apply himself as of May 2012 as CEO of the IBA Group.

Yves Jongen

Chief Research Officer,
Based in Louvain-la-Neuve, Belgium

Yves Jongen is Chief Research Officer for Ion Beam Applications. After founding IBA in 1986, he served as general manager and co-general manager of the company until March 2000, when he assumed his current role. Founded in Louvain-la-Neuve, Belgium, IBA has become a world leader in particle accelerator technology and its applications, particularly in medical imaging, cancer therapy and sterilization.

Prior to founding IBA, Mr. Jongen served for 16 years as manager of the UCL Cyclotron Research Center, a multidisciplinary organization established by the Catholic University of Louvain-la-Neuve (UCL), with several cyclotrons for fundamental and applied research. He holds a dozen patents and is the author of approximately 200 publications in the particle accelerator field and their applications.

Mr. Jongen graduated cum laude from UCL in 1970 as a Civil Engineer in electronics and earned an additional certificate in nuclear sciences. He has received the Georges Vanderlinden prize for science, given by the Belgium Royal Academy, for his work in Physics and Electricity, and shared the magazine Trends-Tendances 1997 Entrepreneur of the year honors for the French speaking part of Belgium with IBA CEO Pierre Mottet.

Board of directors


  • Sybille Van Den Hoverepresenting Median SCP
    • Member of the IBA Board of Directors since May 2015
    • Director , Median SCP, Barcelona
    • Visiting Professor, Institute of Environmental Sciences and Technologies (ICTA), Autonomous University of Barcelona
    • Chair, Scientific Committee, European Environment Agency
  • Dr. Mary Gospodarowicz
    • Member of the IBA Board of Directors since August 2012
    • Professor, Department of Radiation Oncology, University of Toronto
    • Medical Director, Princess Margaret Cancer Centre, Toronto
    • Radiation Oncologist, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto
    • Regional Vice President, Cancer Care Ontario, Toronto
    • President, Union of International Cancer Control
  • Marcel Millerrepresenting Consultance Marcel Miller SCS
    • Member of the IBA Board of Directors since May 2011
    • Currently Chief Executive Officer of Alstom Belgium
    • Formerly Chief Executive Officer of Cherokee Europe
  • Kathleen Vandeweyerrepresenting Kathleen Vandeweyer Comm. V
    • Member of the IBA Board of Directors since May 2013
    • Chief Financial Officer Atos
* Presented as candidates for the position of Independent Directors when they were elected, not excluding the fact that other directors also satisfy the independence criteria.


  • Olivier Legrain
    • Member of the IBA Board of Directors since May 2012
    • Chief Executive Officer and Managing director since May 2012. Start of mandate : 09/05/2012. Member of the nomination committee
  • Yves Jongen
    • Member of the IBA Board of Directors since May 1991
    • Founder of IBA and Chief Research Officer Managing Director since 1991. Start of mandate: 05/29/1998.
    • Before the creation of IBA in 1986, Director of the Cyclotron Research Center at the Catholic University of Louvain (UCL)
  • Pierre Mottet
    • Chairman of the Board since May 2013 and Member of the IBA Board of Directors since May 1998
    • Vice Chairman of the Board of Directors of Agoria
    • Vice Chairman of the Board of Directors of E­Capital
** In accordance with the definition provided in the Articles of Association under the paragraph "Executive Directors"


  • Jeroen Cammeraat
    • Member of the IBA Board of Directors since May 2014
    • Currently Chief Executive Officer of i-Optics
    • Formerly Chief Operating Officer of Nucletron
  • Eric de Lamotterepresenting SA Bayrime
    • Member of the IBA Board of Directors since February 2000. Member of the Audit Committee, the Remuneration Committee and the Nomination Committee
    • Start of mandate: 05/10/2000
    • Director serving on the Board of several companies
    • Formerly Chief Financial Officer (1991-2000) of IBA

Our history

Download our History
  • 1986

    Founding of IBA

    Founded by Yves Jongen in 1986, IBA is as a spin-off of the Cyclotron Research Center of the Catholic University of Louvain-la-Neuve (UCL), Belgium. Initially active in medical imaging, the company turned its attention to radiotherapy and developed cyclotrons and integrated proton therapy centers which are able to treat numerous forms of cancer with a degree of precision and efficacy never reached before.

  • 1992

    IBA expands its activities

    In 1992, IBA expands activities into the industrial sector of sterilization and ionization by introducing the Rhodotron®, a new type of particle accelerator producing an electron beam based on a patented concept of the French Atomic Energy Commission.

  • 1997

    Employee’s Buy Out

    IBA employees got together in 1997 in an employee buyout of the shares of the company. The purpose was to raise their involvement in, and reward their commitment to, the success of the company while also giving themselves the opportunity to drive its future.

  • 1998

    IBA revolutionizes the proton therapy world

    In 1998 IBA introduces a cyclotron revolutionizing the world of proton therapy. The IBA isochronous cyclotron-based solution is today the simplest and most effective way to produce 230 MeV protons and will be used in more than 20 Proton therapy centers all over the world.

  • 1998

    IBA enters the Brussels stock market

    In June 1998, funds are raised on the Brussels stock market from an initial public offering to enable IBA to accelerate development through internal growth and acquisitions.

  • 1998/1999

    IBA enters the field of dosimetry

    IBA enters the field of dosimetry through the acquisition of Scanditronix and Wellhöfer. The new entity called IBA Dosimetry represents the most important player worldwide in the dosimetry market and reinforces IBA's presence in the medical world.

  • 1999

    IBA consolidates its strength in irradiation technologies

    IBA consolidates its strength in irradiation technologies with the acquisition of Radiation Dynamics, Inc. in February 1999. RDI was well established in the field of high-power low-energy E-beam accelerators used for heat shrinking and polymer modification applications.

  • 2001

    IBA develops its presence in the radiopharmaceutical sector:

    Acquisition of Eastern Isotopes. In 2001, IBA becomes the majority shareholder of Eastern Isotopes, Inc., founded in 1993 in Sterling, Virginia, USA. Eastern Isotopes produces standard nuclear medicine products, while expanding into new PET imaging products, most notably FDG. The acquisition allows IBA to leverage its global expertise and innovation, and to offer its customers an international distribution network, more research isotopes and greater access to advanced cyclotron technology.

  • 2001

    First patient treated in an IBA clinical Proton Therapy (PT) center at MGH

    In 2001, the first patient is treated with a PT system installed by IBA at the Massachusetts General Hospital in Boston (now known as the Francis H. Burr Proton Therapy Center). Since then, through relentless effort and commitment, IBA has installed over half of the clinically driven PT centers worldwide and has become the undisputed leader in the field.

  • 2004

    Expansion of proton therapy centers treating patients

    In 2004, the Indiana University Health Proton Therapy Center in Bloomington, Indiana (USA) treats its first patient using protons. A few months later, the Wanjie Proton Therapy Center in Zibo, China, starts treating patients with protons.

  • 2006

    For its 20th anniversary IBA focuses on the fight against cancer

    On April 20th 2006, IBA reveals its new corporate identity expressing its focus on the fight against cancer and its mission to Protect, Enhance and Save Lives. The different companies acquired throughout the years and IBA core activities are integrated in business units to form today’s worldwide group.

  • 2006-2008

    IBA develops its presence in Europe

    IBA activities for the production and distribution of radiopharmaceuticals are developed in Europe through the acquisition of the Schering radiopharmaceutical business and CIS bio International, making IBA the largest European PET radio-isotopes network. As a second step, in 2008, IBA fully acquires the CISBIO organization with a complete line of SPECT radiopharmaceuticals and additional FDG production facilities. The acquisition of CISBIO makes the company one of the world's largest players in the radiopharmaceutical business.

  • 2007

    Developing presence in Asia

    In June 2007, IBA opens a new facility in Beijing, China, giving the company Asian Headquarters to support all its business units in Asia. This move is part of an overall development program to optimize opportunities in one of the world’s fastest growing markets.

  • 2008

    Treating with Pencil Beam Scanning

    In 2008, the highly precise treatment mode “Pencil Beam Scanning”, developed in collaboration with Massachusetts General Hospital (MGH), is approved by the U.S. Food and Drug administration. A few months later, physicians at MGH’s Francis H. Burr Proton Therapy Center use Pencil Beam Scanning to treat patients.

  • 2008

    IBA invests in cutting-edge medical technology:

    Acquisition of CISBIO's drug discovery activities. For more than 25 years, CISBIO Bioassays, now a member of the IBA Group, has explored biology and immunoassay design to provide physicians, biologists, clinical chemists and scientists with enhanced solutions for improving patient care. CISBIO Bioassays dedicates its expertise to delivering cutting-edge assays and services to clinical medicine and pharmaceutical research.

  • 2009

    Successful developments in proton therapy

    In 2009, IBA’s proton therapy activity continues to grow with more successful developments in the field. The four beam modes of IBA’s Universal Nozzle, an all-in-one integrated system to treat patients, are utilized by physicians. Physicians at ProCure Treatment Center in Oklahoma City, Oklahoma (USA) use the new Inclined-beam Treatment Room and deploy the new Empath® 360°gantry room to treat patients.

  • 2012

    IBA creates a strategic alliance for its Molecular Imaging division

    IBA creates a strategic alliance with SK Capital Partners to create IBA Molecular Imaging, a jointly-owned company derived from IBA’s Molecular Imaging division. SK Capital Partners owns 60% of the company while IBA has a 40% stake.

  • May 2012

    Olivier Legrain appointed as Chief Executive Officer of IBA

    Olivier Legrain becomes Chief Executive Officer replacing Pierre Mottet. Olivier Legrain joined the company in 1996 as Financial Controller. He further pursued his career in the company as President of the IBA Dosimetry business line from 1999 to 2003. From 2003 till 2010 he became President of the IBA Molecular business line. Thereafter he took over the role of Chief Strategy Officer of the Group.

  • 2013

    Yves Jongen nominated for the European Inventor Award

    Yves Jongen, Founder and Chief Research Officer of IBA, is nominated for the European Inventor of the Year Award from the European Patent Office for his lifetime contribution to developing new solutions in proton therapy and making this next generation targeted cancer treatment more accessible to cancer patients worldwide.

  • 2013

    IBA Group sells Cisbio Bioassays

    Following its strategy to focus on its proton therapy, accelerators and dosimetry activities, IBA sells Cisbio Bioassays, to Argos Soditic. Cisbio Bioassays develops and markets products and technologies used for in vitro diagnostics and drug discovery.

Prev Next

    Quality Management

    Quality, Environment, Health and Safety Management

    It is our Quality Policy to meet or exceed our defined customer’s expectations in all products and service provisions. This will be done by understanding and focusing on performance measures that are critical to our customer’s success. An important part of this is about meeting regulatory requirements.

    what are our expectations?

    Therefore, each of us in the IBA group is expected to be part of:

    • Developing and following-up action plans to continuously ensure regulatory compliance of each Business within the Group for equipment delivery and pharmaceuticals production and distribution.
    • Deploying worldwide harmonized best practices, ensure consistency across all Business Units, and coordinating multi-year programs on Regulatory Affairs management and Quality-Environment-Safety management
    • Anticipating the impacts of Regulatory changes in all regions where IBA is present
    • Making continuous monitoring of our key processes and our organization through yearly regulatory, environmental and safety audits within the Group using essential Key Performance Indicators
    Download quality policy document

    Environmental Health and Safety CEO’s Policy statement

    Our vision is to achieve sustainable business success through excellence in environment, health and safety!

    Sustainable business advantage starts when we understand and address Environment, Health and Safety (EHS) issues, we have our own internal standards and systems to ensure that we comply with or exceed all guidelines, regulations and legal requirements.

    what are the plans of IBA?

    IBA requires all Business Units and plants to:

    • Establish business practices on environment, health, safety and loss prevention strategies that optimally use resources and prevent incidents, pollution... Make environment, health, safety and loss prevention integral to all IBA business processes, planning and decision making; Therefore the EHS responsible and Management of each Business Unit should manage its own yearly objectives and associated actions implementing the Corporate Policy
    • Protect the health and safety of our employees, contractors, visitors and others affected by our operations
    • Communicate on EHS to always keep all IBA employees aware and responsive for participating actively in, and accept individual responsibility for environment, health and safety matters and work in partnership with management to assure compliance and support continuous improvement
    • Comply with legal requirements and global IBA environment, health and safety standards trough implementing an ISO14001 and OSHA 18001 compliant management system;
    • Commit to continuous improvement of environment, health and safety performance in order to eliminate or mitigate all detected risk in an ALARP approach and do this in a proactive manner (objectives settings, specific policies and practices improvements, crisis communication plans…) rather than only treat the risks once they occur.
    • Download EHS Policy statement
    Olivier Legrain
    Chief Executive Officer

    Customer Support

    Back to top